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Abstract
Background—Excellent long-term outcomes have been reported recently for patients with small
(≤2 cm) hepatocellular carcinoma (HCC). However, the significance of microvascular invasion
(MVI) in small HCC remains unclear. The purpose of this study was to determine the impact of
MVI in small HCC up to 2 cm.
Methods—In 1,109 patients with solitary HCC from six major international hepatobiliary
centers, the impact of MVI on long-term survival in patients with small HCC (≤2 cm) and patients
with tumors larger than 2 cm was analyzed.
Results—In patients with small HCC, long-term survival was not affected by MVI (p = 0.8),
whereas in patients with larger HCC, significantly worse survival was observed in patients with
MVI (p < 0.0001). In multivariate analysis, MVI (hazard ratio [HR] 1.59; 95 % confidence
interval (CI) 1.27–1.99; p < 0.001), elevated alpha-fetoprotein (HR 1.41; 95 % CI 1.11–1.8; p =
0.005), and higher histologic grade (HR 1.29; 95 % CI 1.01–1.64; p = 0.04) were significant
predictors of worse survival in patients with HCC larger than 2 cm but were not correlated with
long-term survival in small HCC. When the cohort was divided into three groups—HCC ≤2, >2
cm without MVI, and HCC >2 cm with MVI—significant between-group survival difference was
observed (p < 0.0001).
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Conclusions—Small HCC is associated with an excellent prognosis that is not affected by the
presence of MVI. The discriminatory power of the 7th edition of the AJCC classification for
solitary HCC could be further improved by subdividing tumors according to size (≤2 vs. >2 cm).
Multiple staging systems have been proposed for stratifying patients with hepatocellular
carcinoma (HCC) according to prognosis and optimal treatment. The 7th edition of the
American Joint Committee on Cancer (AJCC) staging system for HCC is one of the most
commonly used staging systems, and its usefulness and clinical relevance have been
validated by various external studies.1–8 However, a limitation of the current AJCC staging
system is that solitary HCC is not stratified with respect to size. Because the selection of
treatment is highly dependent on tumor size in the era of multimodality treatment for HCC,
it is practically important to clarify the clinical significance of tumor size using a large
international population.
Recently, excellent long-term outcomes in patients with solitary HCC up to 2 cm have been
reported in several studies.9–14 This size cutoff of 2 cm has been adopted in the 5th edition
of the Liver Cancer Study Group of Japan (LCSGJ) classification and in the Barcelona
Clinic Liver Cancer (BCLC) staging system.15,16 In addition to tumor size, the presence of
microvascular invasion (MVI) has been reported to be a strong prognostic factor in
HCC.17–20 However, the significance of MVI in small HCC has not yet been clarified.
Accordingly, the definition of the earliest stage of solitary HCC varies among the staging
systems.
Given these areas of ambiguity and the frequent clinical presentation of solitary HCC, the
purpose of this study was to clarify the clinical significance of MVI in HCC up to 2 cm to
further optimize the current AJCC classification for solitary HCC.
PATIENTS AND METHODS
Study Cohort and Clinicopathologic Variables
The Institutional Review Board of The University of Texas MD Anderson Cancer Center
approved this study protocol. We identified 1,975 patients who underwent curative resection
of HCC between 1981 and 2011 at six major hepatobiliary centers: MD Anderson Cancer
Center (Houston, TX, USA), University of Tokyo (Tokyo, Japan), Mayo Clinic (Rochester,
MI, USA), Hôpital Beaujon (Paris, France), Hôpital Henri Mondor (Créteil, France), and
Queen Mary Hospital (Hong Kong, China). To permit assessment of prognostic factors in
solitary HCC, we excluded patients with multiple tumors (n = 651), major vascular invasion
(n = 160), extrahepatic disease (i.e., positive lymph nodes or metastases; n = 17), or tumor
invasion of other organs or tumor rupture (n = 34). Four patients with incomplete pathologic
data also were excluded from this study. The remaining 1,109 patients comprised the final
cohort and were studied in detail.
Patients were considered positive for hepatitis B virus if they had hepatitis B surface antigen
or antihepatitis B core antibody. Patients were considered positive for hepatitis C virus if
they had antihepatitis C virus antigen. Tumor size was based on the largest dimension of the
tumor in the resected specimen. Patients were considered to have MVI if they had
microscopic tumor emboli within the central hepatic vein, the portal vein, or the large
capsular vessels. Tumor grade was assessed using the scheme outlined by Edmondson and
Steiner21 and was recorded based on the highest grade in a specimen. The degree of fibrosis
was assessed on the basis of the Ishak score, and grades F5 and F6 were considered
cirrhosis.22
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Statistical Analysis
Statistical analysis was performed using IBM SPSS software (version 19.0, SPSS Inc.,
Chicago, IL) and JMP 9.0 software (SAS Institute Japan, Tokyo, Japan). Medians and
ranges of continuous variables were compared using the Mann–Whitney U test. Categorical
variables were compared using Pearson’s χ2 test or Fisher’s exact test as appropriate.
The rationale for adopting the cutoff value of 2 cm for solitary HCC was confirmed by the
minimum p value approach to predict survival after surgical resection. The hazard ratio
(HR) was highest and p value was lowest at 2 cm (HR 1.83; 95 % confidence interval (CI)
1.37–2.49; p < 0.0001) when sliding the cutoff value from 1 cm through 10 cm.
Survival curves were generated using the Kaplan–Meier method and were compared by log-
rank test. To determine the interaction between the size cutoff of 2 cm and the presence of
MVI, survival curves were compared between the patients with and without MVI stratified
by tumor size. To identify prognostic factors, a multivariate regression analysis was
performed using the Cox proportional hazard model for the variables with p < 0.05 in
univariate analysis.
RESULTS
Clinicopathologic Characteristics
The median age of the 1,109 patients with solitary HCC was 62 years (range 4–87); 809
patients (72.9 %) were men. Of the 1,109 patients, 1,030 (92.9 %) were classified as Child–
Pugh A, and the remaining 79 patients (7.1 %) were Child–Pugh B. Among the 747 patients
for whom the results of hepatitis C virus serologic tests were available, 324 (43.4 %)
patients were positive for hepatitis C. Among the 996 patients for whom the results of
hepatitis B virus serologic tests were available, 401 (40.3 %) patients were positive for
hepatitis B. Median tumor size was 4.8 cm (range 0.5–27), and 155 patients (14 %) were
classified as having small (≤2 cm) HCC. Histopathologically, MVI was identified in 375
patients (33.8 %), and approximately half of the patients (506; 45.6 %) had cirrhosis. The
median follow-up period was 40.3 months (range 1–205).
Long-Term Survival According to Current Staging Systems
Patients’ disease was classified on the basis of size of HCC and presence of MVI according
to three current staging systems: AJCC 7th edition, LCSGJ 5th edition, and BCLC staging
system. Within each staging system, the survival rates of patients with different stages of
disease were compared (Fig. 1). The patients were well-stratified by all three staging
systems. For patients with stages I and II disease according to the AJCC 7th edition, the
median survival durations were estimated to be 84.7 and 60.6 months, respectively (p <
0.0001). In the LCSGJ 5th edition and BCLC staging systems, the prognostic advantage
associated with small HCC (≤2 cm) was clear: the median survival duration of the LCSGJ
stage I was 126.9 months and that of the BCLC stage 0 was 101.3 months, respectively.
Prognostic Impact of MVI in HCC up to 2 cm
In patients with HCC up to 2 cm, long-term survival was not influenced by the presence of
MVI (p = 0.8). However, in patients with HCC larger than 2 cm, patients with MVI had
significantly worse survival (p < 0.0001; Fig. 2). The characteristics of patients with tumors
up to 2 cm with and without MVI are shown in Table 1. Histologic grade and serum alpha-
fetoprotein level were higher in the patients with MVI than in those without MVI. Other
demographic and clinical factors did not differ significantly between the two groups.
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Prognostic Factors by Tumor Size
In patients with HCC up to 2 cm, none of the studied factors were significantly associated
with long-term survival in the univariate analysis (Table 2). However, in patients with HCC
larger than 2 cm, three factors were significant predictors of worse overall survival in both
univariate and multivariate analysis: presence of MVI (HR 1.59; 95 % CI 1.27–1.99; p <
0.001), alpha-fetoprotein level higher than 10 ng/mL (HR 1.41; 95 % CI 1.11–1.8; p =
0.005), and higher histologic grade (HR 1.29; 95 % CI 1.01–1.64; p = 0.04).23
Reclassification of Solitary HCC
On the basis of these results, we reclassified solitary HCC into three groups—up to 2 cm,
larger than 2 cm without MVI, and larger than 2 cm with MVI—and compared the survival
curves for these groups (Fig. 3a). There were significant prognostic differences among these
three groups.
We also compared the survival curves for these three groups with the survival curves
generated for the patients with multiple HCC who were identified in our initial search for
patients who underwent curative resection of HCC between 1981 and 2011 but excluded
from the final cohort because of their multiple HCC. The survival curve of patients with
solitary HCC larger than 2 cm with MVI was quite similar to that of patients with multiple
HCC up to 5 cm (median survival, 55 versus 55.9 months; p = 0.53; Fig. 3b). When we
modified the current AJCC 7th edition classification to take into account tumor size and
MVI in patients with solitary HCC (Table 3), clear prognostic stratification was obtained,
and patients with solitary HCC up to 2 cm had a better prognosis than those with solitary
HCC larger than 2 cm (Fig. 3c).
DISCUSSION
In this study, we analyzed the influence of tumor size and MVI on the long-term survival of
1,109 patients with solitary HCC. Our findings indicate that neither MVI nor histologic
grade has an impact on long-term survival in patients with HCC measuring up to 2 cm and
suggest the possibility of dividing the T1 category in the current AJCC 7th edition staging
system into T1a, for patients with solitary HCC up to 2 cm irrespective of MVI, and T1b, for
patients with solitary HCC larger than 2 cm without MVI.
To date, various staging systems have been used to stratify patients with HCC with respect
to prognosis and to help select optimal therapeutic options for patients with HCC.17,24–26 In
most classification systems, T category is determined by tumor size, tumor number,
presence/absence of MVI, presence/absence of major vascular invasion, or tumor invasion
or rupture. The current AJCC 7th edition classification is a modification of a simplified
staging system established by extensive prognostic analysis of HCC, and its clinical
relevance has been validated in various studies.2–8,26,27 However, a limitation of the current
edition of the AJCC classification is that all solitary HCCs without MVI are classified as
stage I regardless of tumor size.
In BCLC and other staging systems, HCC measuring up to 2 cm is considered “early HCC”
and is associated with a high rate of surgical cure. This specific subset of HCC has been
reported to be less oncologically aggressive and is characterized by excellent prognosis after
surgical resection, radiofrequency ablation, or transplantation.9,12–14,28–30 The current study
confirms that HCC up to 2 cm is associated with a favorable prognosis: patients with such
tumors had a median survival of 10 years after surgical resection. Another noteworthy result
is that neither MVI nor histologic grade affected overall survival in patients with HCC
measuring up to 2 cm, whereas these pathologic factors were significantly associated with
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long-term survival in patients with HCC larger than 2 cm. These data correlate with recent
studies from Japan and the west that reported MVI had no significant impact on overall
survival in patients with HCC up to 2 cm.10,31 Although we have not investigated
recurrence-free survival, our results are compatible with the results of these studies.
From a clinical standpoint, our results are practically important. First, various curative
therapeutic options can be selected for such small tumors, including surgical resection,
radiofrequency ablation, or transplantation, according to the underlying liver function and
the patient’s performance status. Second, because histopathologic features have no effect on
the prognosis of patients with HCC up to 2 cm, resection for the purpose of pathologic
evaluation might not be necessary in patient selection for liver transplantation.32,33
On the basis of these results, we modified the current AJCC classification system by
integrating a size cutoff of 2 cm for solitary HCC. When we classified solitary HCC up to 2
cm as T1a, solitary HCC larger than 2 cm without MVI as T1b, and solitary HCC larger than
2 cm with MVI as T2, the current AJCC classification was better able to stratify the outcome
of patients with early HCC. Furthermore, the survival curve for solitary HCC larger than 2
cm with MVI was quite similar to that for multiple HCC up to 5 cm. Therefore, these two
groups can be grouped together in a revised T2 category.
The limitations of this study include its retrospective nature and selected population.
However, the clinical data from each of the six participating hepatobiliary centers were
collected prospectively, and importantly, these data are from various countries in North
America, Europe, and Asia. In addition, because the current data are for patients treated only
with surgical resection, validation using patients who received nonsurgical treatment may be
needed. Furthermore, very small number of patients having MVI in small HCC might raise
the possibility of type II error in statistical analysis. However, the patients with HCC
measuring up 2 cm actually have good prognosis and the current results are consistent with
the reported outcomes of two recent studies investigating small HCC.10,31
In conclusion, MVI does not affects long-term survival in patients with HCC up to 2 cm.
Integration of a size cutoff of 2 cm may improve the ability of the current AJCC staging
system to stratify outcomes of patients with small HCC.
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FIG. 1.
Survival of patients with solitary hepatocellular carcinoma according to current staging
systems. a American Joint Committee on Cancer 7th edition. b Liver Cancer Study Group of
Japan 5th edition. c Barcelona Clinic Liver Cancer staging system
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FIG. 2.
Survival of patients with solitary hepatocellular carcinoma according to presence of
microvascular invasion (MVI). a Tumor size 0–2 cm.
b Tumor size >2 cm
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FIG. 3.
Survival of patients with solitary hepatocellular carcinoma according to tumor size and
microvascular invasion (MVI) and new classification of hepatocellular carcinoma (HCC). a
Comparison of survival according to size cutoff value of 2 cm and MVI. b Comparison of
new classification for solitary tumor and current classification of multiple HCC. c Proposed
new classification by stage (stages as outlined in Table 3)
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TABLE 1
Characteristics of patients with HCC up to 2 cm by MVI status
Characteristic MVI−
(n = 114)
MVI+ (n = 41) p
Age (years), median (range) 62.5 (28–82) 63 (11–78) 0.57
Gender, male 86 (75.4) 27 (65.9) 0.24
Hepatitis C positivea 42 (36.8) 17 (41.5) 0.59
Hepatitis B positiveb 40 (35.1) 17 (41.5) 0.77
Child–Pugh class 0.54
  A 102 (89.5) 38 (92.7)
  B 12 (10.5) 3 (7.3)
Tumor size (cm), median (range) 1.7 (0.5–2.0) 1.8 (0.9–2.0) 0.42
Histologic gradec 0.04
  Well differentiated 26 (24.3) 2 (4.9)
  Moderately differentiated 64 (59.8) 28 (68.3)
  Poorly differentiated 17 (15.9) 11 (26.8)
  Unknown 7 (6.1) 0 (0)
Liver cirrhosisd 69 (60.5) 24 (58.5) 0.82
AFP (ng/mL), median (range) 14 (1–6417) 82 (1.6–135094) 0.02
Type of resection 0.82
  Minor 105 (92.1) 38 (92.7)
  Major 9 (7.9) 3 (7.3)
Microscopic margin status 0.31
  Positive 2 (1.9) 2 (4.9)
  Negative 105 (98.1) 39 (95.1)
Values are number of patients (percentage) unless otherwise indicated HCC hepatocellular carcinoma, MVI microvascular invasion, AFP alpha-
fetoprotein
a
Missing data in 33 cases
b
Missing data in 11 cases
c
Edmondson grade21
d
Ishak score F5 or F622
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